Related Experiment Video
Updated: Jul 29, 2025
Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
Published on: June 23, 2020
Design of Novel Letrozole Analogues Targeting Aromatase for Breast Cancer: Molecular Docking, Molecular Dynamics, and
Alaa Edris1, Mohammed Abdelrahman2, Wadah Osman3,4
1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Gezira, Wad Madani 21111, Sudan.
Abstract:
The use of aromatase inhibitors is an established therapy for estrogen-dependent breast cancer in postmenopausal women. However, the only commercially available aromatase inhibitor, letrozole, is not highly selective; in addition to aromatase, it has an affinity for binding to desmolase, an enzyme involved in steroidogenesis, which explains the main side effects. Therefore, we designed new compounds based on the structure of letrozole. More than five thousand compounds were constructed based on the letrozole structure. Then, these compounds were screened for their binding ability toward the target protein, aromatase. Quantum docking, Glide docking, and ADME studies showed 14 new molecules with docking scores of ≤-7 kcal/mol, compared to the docking score of -4.109 kcal/mol of the reference, letrozole. Moreover, molecular dynamics (MD) and post-MD MM-GBSA calculations were calculated for the top three compounds, and the results supported in their interaction's stability. Finally, the density-functional theory (DFT) study applied to the top compound to study the interaction with gold nanoparticles revealed the most stable position for the interaction with the gold nanoparticles. The results of this study confirmed that these newly designed compounds could be useful starting points for lead optimization. Further in vitro and in vivo studies are recommended for these compounds to verify these promising results experimentally.
Insights
Researchers designed novel compounds to improve upon letrozole, a breast cancer drug. These new molecules show higher binding affinity for aromatase, suggesting potential for more effective and selective cancer therapies.
Area of Science:
- Medicinal Chemistry
- Computational Drug Design
- Oncology
Background:
- Aromatase inhibitors are standard treatment for estrogen-dependent breast cancer in postmenopausal women.
- Letrozole, a widely used aromatase inhibitor, lacks selectivity, binding to desmolase and causing side effects.
- There is a need for more selective and potent aromatase inhibitors.
Purpose of the Study:
- To design and computationally evaluate novel compounds with improved selectivity and binding affinity for aromatase.
- To identify potential lead compounds for the development of next-generation breast cancer therapeutics.
Main Methods:
- Over 5,000 letrozole-based compounds were designed and computationally screened.
- Quantum docking, Glide docking, and ADME studies were performed to assess binding affinity and drug-likeness.
- Molecular dynamics (MD) and MM-GBSA calculations evaluated the stability of top-ranked compounds.
- Density-functional theory (DFT) was used to study the interaction of the lead compound with gold nanoparticles.
Main Results:
- 14 novel compounds exhibited superior docking scores (≤-7 kcal/mol) compared to letrozole (-4.109 kcal/mol).
- MD and MM-GBSA studies confirmed the stable interactions of the top three compounds.
- DFT analysis identified a stable interaction mode between the lead compound and gold nanoparticles.
- The designed compounds show promise as starting points for drug optimization.
Conclusions:
- The newly designed compounds demonstrate significant potential as selective aromatase inhibitors.
- These compounds represent promising candidates for further development in breast cancer therapy.
- In vitro and in vivo studies are recommended to validate these computational findings.
